Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the discovery and development of oral peptide-based therapies that address unmet needs in immune-mediated and hematologic diseases. Headquartered in Newark, California, with research operations in Cambridge, Massachusetts, Protagonist leverages its proprietary Peptelligence platform to design and optimize peptide analogs for selective targeting of complex biological pathways. The company’s scientific approach emphasizes oral delivery and modular peptide structures to improve patient convenience and therapeutic precision.
The company’s most advanced candidate, PTG-200, is an oral interleukin-23 receptor antagonist in Phase 2 development for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. PTG-300, an oral hepcidin mimetic designed to regulate iron homeostasis, is being evaluated for the treatment of anemia associated with chronic diseases such as myelofibrosis and polycythemia vera. Earlier-stage programs include PTG-100, an oral antagonist of the α4β7 integrin that is being studied for ulcerative colitis, as well as several preclinical peptide modulators aimed at rare immunological conditions and select oncology indications.
Since its founding in 2012, Protagonist has pursued a strategy of advancing multiple clinical programs in parallel, while forging collaborations to expand its global footprint. The company maintains partnerships and licensing arrangements to support development and commercialization in key markets, including North America, Europe and Asia. Protagonist’s global operations encompass clinical trial activities, regulatory submissions and manufacturing partnerships that underpin its late-stage pipeline efforts.
Under the leadership of President and Chief Executive Officer Leen Kawas, Ph.D., Protagonist employs an experienced management team with deep expertise in peptide drug discovery, clinical development and global regulatory affairs. The board and scientific advisory panels include biopharma veterans who guide strategic development priorities. As a publicly traded company on the NASDAQ exchange, Protagonist is dedicated to advancing its innovative oral peptide therapeutics toward regulatory approval and broad patient access.
AI Generated. May Contain Errors.
Free PTGX Stock Alerts